AU2003286142A1 - Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis - Google Patents

Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Info

Publication number
AU2003286142A1
AU2003286142A1 AU2003286142A AU2003286142A AU2003286142A1 AU 2003286142 A1 AU2003286142 A1 AU 2003286142A1 AU 2003286142 A AU2003286142 A AU 2003286142A AU 2003286142 A AU2003286142 A AU 2003286142A AU 2003286142 A1 AU2003286142 A1 AU 2003286142A1
Authority
AU
Australia
Prior art keywords
lallminin
metastasis
antibodies
gamma
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286142A
Inventor
Sirpa Salo
Karl Tryggvason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003286142A1 publication Critical patent/AU2003286142A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003286142A 2002-10-29 2003-10-29 Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis Abandoned AU2003286142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42200902P 2002-10-29 2002-10-29
US60/422,009 2002-10-29
PCT/EP2003/012012 WO2004039401A2 (en) 2002-10-29 2003-10-29 Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Publications (1)

Publication Number Publication Date
AU2003286142A1 true AU2003286142A1 (en) 2004-05-25

Family

ID=32230306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286142A Abandoned AU2003286142A1 (en) 2002-10-29 2003-10-29 Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Country Status (6)

Country Link
EP (1) EP1578444A2 (en)
JP (1) JP2006511493A (en)
AU (1) AU2003286142A1 (en)
CA (1) CA2502088A1 (en)
MX (1) MXPA05004126A (en)
WO (1) WO2004039401A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534631A (en) * 2003-10-28 2007-11-29 ノボ ノルディスク アクティーゼルスカブ Laminin-5γ2 binding peptides, related compositions and uses thereof
WO2005052003A2 (en) * 2003-11-20 2005-06-09 Biostratum, Inc. Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
US8545845B2 (en) * 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955924B2 (en) * 1994-10-04 2005-10-18 Biostratum, Inc. Laminin chains: diagnostic uses
US5660982A (en) * 1994-10-04 1997-08-26 Tryggvason; Karl Laminin chains: diagnostic uses
EP1326892A2 (en) * 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
EP1424558A4 (en) * 2001-08-17 2004-12-15 Eisai Co Ltd Reagent for assaying laminin 5 antigen in biological sample and assay method

Also Published As

Publication number Publication date
JP2006511493A (en) 2006-04-06
WO2004039401A2 (en) 2004-05-13
WO2004039401A3 (en) 2004-06-03
EP1578444A2 (en) 2005-09-28
MXPA05004126A (en) 2005-10-18
CA2502088A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
HK1208472A1 (en) Antibodies that bind cell-associated ca 125/o722p and methods of use thereof ca125/o772p
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
EP1546112A4 (en) Imidazolopyridines and methods of making and using the same
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
HK1091132A1 (en) Anti-cd33 antibodies and the use thereof -cd33
AU2003224638A1 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
IL164021A0 (en) Antibodies and anti-pharmaceutical compositions containing the same
AU2003298998A1 (en) Oriented nanostructures and methods of preparing
AU2003205913A1 (en) Materials and methods relating to cancer diagnosis
IL165819A0 (en) Method of producing organic material and use of the same
AUPS305702A0 (en) Superconducting material and method of synthesis
AU2003239610A8 (en) Tiled biochips and the methods of making the same
AU2003219093A1 (en) Anti-hpv-16 e7 antibodies and their use
AU2003286142A1 (en) Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis
AU2003228450A1 (en) Inhibition of tumor growth via peroxiredoxin 3
EP1581496A4 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2003205751A8 (en) Plant growth modulation by drl1 and other proteins of the elongator complex
AU2003297906A1 (en) Modulation of interleukin 18 expression
WO2005042707A9 (en) Taspasel 1 and methods of use
AU2003215725A1 (en) Materials and methods relating to the treatment of lymphoma
AU2003297181A1 (en) Compositions and methods for inhibiting tumor growth and metastasis
AU2003249364A8 (en) Algal gdp-mannose-3',5'-epimerases and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase